MB-217

N/A

Report date: 2023/12/20 18:00:43

Base Information

Drug NameMB-217

Drug Alias NameCL20-4i-EF1alpha- HgammaC-OPTCL20-i4-EF1α-hγc-OPTEx vivo gene therapy(Mustang Bio)Gene-modified CD34+ hematopoietic stem cells therapy(Mustang Bio)Lentiviral genetherapy(Mustang Bio) +[9]

ClassificationCell and gene therapy > Gene therapy

Mechanisms of ActionIL-2RG gene transference

TargetsInterleukin-2 receptor subunit gamma

Therapy Area/IndicationsSevere Combined Immunodeficiency

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesMustang Bio Inc

China Registration ClassN/A

Develop Information

Active CompaniesMustang Bio Inc

Inactive CompaniesN/A

Active IndicationsSevere Combined Immunodeficiency

Inactive IndicationsN/A

Other Information

ATC CodeN/A